China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
U.S.–Taiwan Trade Deal Spurs $500 Billion Semiconductor Investment in America 
One Percent Rule Checklist For Safer Forex Trading Risk 
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
AFT Leaves X Over AI-Generated Images of Minors 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
AstraZeneca (NASDAQ:AZN) has announced plans to acquire biotechnology company EsoBiotec for up to $1 billion, aiming to advance its cell therapy capabilities, particularly for cancer and autoimmune treatments. The deal includes an upfront payment of $425 million and up to $575 million in milestone-based payments. Expected to close in Q2 2025, the acquisition will not impact AstraZeneca’s financial guidance for this year.
This move aligns with AstraZeneca’s strategy to strengthen its position in oncology and cell therapy. The pharmaceutical giant has been expanding aggressively, acquiring China-based Gracell Biotechnologies for $1.2 billion in December 2023 and investing $300 million in Maryland for cell therapy research earlier this year.
CEO Pascal Soriot emphasized that emerging technologies, such as antibody-drug conjugates (ADC) and cell therapy, are becoming key components of AstraZeneca’s drug pipeline. EsoBiotec’s cutting-edge platform enables the genetic modification of immune cells directly inside the body, significantly reducing treatment time from weeks to minutes.
By integrating EsoBiotec’s breakthrough technology, AstraZeneca aims to accelerate the development of next-generation therapies, enhancing its position in the competitive biotech landscape. As the demand for innovative cancer treatments rises, this acquisition reinforces AstraZeneca’s commitment to pioneering advancements in precision medicine and immunotherapy.
